30 results on '"Rajahram, Giri S"'
Search Results
2. Longitudinal changes in iron homeostasis in human experimental and clinical malaria
- Author
-
Woolley, Stephen D., Grigg, Matthew J., Marquart, Louise, Gower, Jeremy S.E., Piera, Kim, Nair, Arya Sheela, Amante, Fiona M., Rajahram, Giri S., William, Timothy, Frazer, David M., Chalon, Stephan, McCarthy, James S., Anstey, Nicholas M., and Barber, Bridget E.
- Published
- 2024
- Full Text
- View/download PDF
3. Evaluation of a point-of-care haemozoin assay (Gazelle device) for rapid detection of Plasmodium knowlesi malaria
- Author
-
Tan, Angelica F., Thota, Priyaleela, Sakam, Sitti Saimah Binti, Lew, Yao Long, Rajahram, Giri S., William, Timothy, Barber, Bridget E., Kho, Steven, Anstey, Nicholas M., Bell, David, and Grigg, Matthew J.
- Published
- 2023
- Full Text
- View/download PDF
4. Quantification of parasite clearance in Plasmodium knowlesi infections
- Author
-
T. Thurai Rathnam, Jeyamalar, Grigg, Matthew J., Dini, Saber, William, Timothy, Sakam, Sitti Saimah, Cooper, Daniel J., Rajahram, Giri S., Barber, Bridget E., Anstey, Nicholas M., Haghiri, Ali, Rajasekhar, Megha, and Simpson, Julie A.
- Published
- 2023
- Full Text
- View/download PDF
5. Is the rise of simian zoonotic malarias a public health problem caused by humans? A review of simian malaria in humans
- Author
-
Woolley, Stephen D., Beeching, Nicholas J., Lalloo, David G., and Rajahram, Giri S.
- Published
- 2023
- Full Text
- View/download PDF
6. Plasmodium vivax malaria serological exposure markers: Assessing the degree and implications of cross-reactivity with P. knowlesi
- Author
-
Longley, Rhea J., Grigg, Matthew J., Schoffer, Kael, Obadia, Thomas, Hyslop, Stephanie, Piera, Kim A., Nekkab, Narimane, Mazhari, Ramin, Takashima, Eizo, Tsuboi, Takafumi, Harbers, Matthias, Tetteh, Kevin, Drakeley, Chris, Chitnis, Chetan E., Healer, Julie, Tham, Wai-Hong, Sattabongkot, Jetsumon, White, Michael T., Cooper, Daniel J., Rajahram, Giri S., Barber, Bridget E., William, Timothy, Anstey, Nicholas M., and Mueller, Ivo
- Published
- 2022
- Full Text
- View/download PDF
7. Neutrophil activation, acute lung injury and disease severity in Plasmodium knowlesi malaria.
- Author
-
Tan, Angelica F., Sakam, Sitti Saimah binti, Piera, Kim, Rajahram, Giri S., William, Timothy, Barber, Bridget E., Anstey, Nicholas M., Grigg, Matthew J., and Kho, Steven
- Subjects
LEUCOCYTES ,LEUCOCYTE elastase ,HOSPITAL admission & discharge ,MALARIA ,NEUTROPHILS - Abstract
The risk of severe malaria from the zoonotic parasite Plasmodium knowlesi approximates that from P. falciparum. In severe falciparum malaria, neutrophil activation contributes to inflammatory pathogenesis, including acute lung injury. The role of neutrophil activation in the pathogenesis of severe knowlesi malaria has not been examined. We evaluated 213 patients with P. knowlesi mono-infection (138 non-severe, 75 severe) and 49 Plasmodium-negative controls from Malaysia. Markers of neutrophil activation (soluble neutrophil elastase [NE], citrullinated histone [CitH3] and circulating neutrophil extracellular traps [NETs]) were quantified in peripheral blood by microscopy and immunoassays. Findings were correlated with malaria severity, ALI clinical criteria, biomarkers of parasite biomass, haemolysis, and endothelial activation. Neutrophil activation increased with disease severity, with median levels higher in severe than non-severe malaria and controls for NE (380[IQR:210–930]ng/mL, 236[139–448]ng/mL, 218[134–307]ng/mL, respectively) and CitH3 (8.72[IQR:3.0–23.1]ng/mL, 4.29[1.46–9.49]ng/mL, 1.53[0.6–2.59]ng/mL, respectively)[all p<0.01]. NETs were higher in severe malaria compared to controls (126/μL[IQR:49–323] vs 51[20–75]/μL, p<0.001). In non-severe malaria, neutrophil activation fell significantly upon discharge from hospital (p<0.03). In severe disease, NETs, NE, and CitH3 were correlated with parasitaemia, cell-free haemoglobin and angiopoietin-2 (all Pearson's r>0.24, p<0.05). Plasma NE and angiopoietin-2 were higher in knowlesi patients with ALI than those without (p<0.008); neutrophilia was associated with an increased risk of ALI (aOR 3.27, p<0.01). In conclusion, neutrophil activation is increased in ALI and in proportion to disease severity in knowlesi malaria, is associated with endothelial activation, and may contribute to disease pathogenesis. Trials of adjunctive therapies to regulate neutrophil activation are warranted in severe knowlesi malaria. Author summary: The most common malaria in Malaysia is caused by animal-to-human transmission of Plasmodium knowlesi from its natural monkey hosts to humans via mosquito bites. As the human immune system responds to such infection, white blood cells such as neutrophils are recruited, activated and release products with pathogen-killing activity. There is increasing evidence that neutrophil products cause damage to the host and contribute to severe disease. While this has been studied in human-only malaria, the role of neutrophils in zoonotic P. knowlesi malaria is poorly understood. In this study, we examined three markers of neutrophil activation (neutrophil elastase, citrullinated histone H3 and neutrophil extracellular traps) in hospital patients with severe and non-severe knowlesi malaria from Sabah, East Malaysia. Compared to healthy controls, neutrophil activation was increased in patients with knowlesi malaria in proportion to disease severity. The increase in neutrophil activation was also linked to different types of severe malaria manifestations, especially acute lung injury. These findings have implications for development of new strategies to prevent host organ damage for better treatment of severe knowlesi malaria. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. An Evaluation of Commonly Used Surrogate Baseline Creatinine Values to Classify AKI During Acute Infection
- Author
-
Cooper, Daniel J., Plewes, Katherine, Grigg, Matthew J., Patel, Aatish, Rajahram, Giri S., William, Timothy, Hiemstra, Thomas F., Wang, Zhiqiang, Barber, Bridget E., and Anstey, Nicholas M.
- Published
- 2021
- Full Text
- View/download PDF
9. Age-Related Clinical Spectrum of Plasmodium knowlesi Malaria and Predictors of Severity
- Author
-
Grigg, Matthew J., William, Timothy, Barber, Bridget E., Rajahram, Giri S., Menon, Jayaram, Schimann, Emma, Piera, Kim, Wilkes, Christopher S., Patel, Kaajal, Chandna, Arjun, Drakeley, Christopher J., Yeo, Tsin W., and Anstey, Nicholas M.
- Published
- 2018
10. Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria : An Open-Label Randomized Controlled Trial CAN KNOW
- Author
-
Grigg, Matthew J., William, Timothy, Barber, Bridget E., Rajahram, Giri S., Menon, Jayaram, Schimann, Emma, Wilkes, Christopher S., Patel, Kaajal, Chandna, Arjun, Price, Ric N., Yeo, Tsin W., and Anstey, Nicholas M.
- Published
- 2018
11. Comparative evaluation of two commercial real-time PCR kits (QuantiFast™ and abTES™) for the detection of Plasmodium knowlesi and other Plasmodium species in Sabah, Malaysia
- Author
-
Nuin, Nor Afizah, Tan, Angelica F., Lew, Yao Long, Piera, Kim A., William, Timothy, Rajahram, Giri S., Jelip, Jenarun, Dony, Jiloris F., Mohammad, Rashidah, Cooper, Daniel J., Barber, Bridget E., Anstey, Nicholas M., Chua, Tock H., and Grigg, Matthew J.
- Published
- 2020
- Full Text
- View/download PDF
12. Updating estimates of Plasmodium knowlesi malaria risk in response to changing land use patterns across Southeast Asia.
- Author
-
Tobin, Ruarai J., Harrison, Lucinda E., Tully, Meg K., Lubis, Inke N. D., Noviyanti, Rintis, Anstey, Nicholas M., Rajahram, Giri S., Grigg, Matthew J., Flegg, Jennifer A., Price, David J., and Shearer, Freya M.
- Subjects
MALARIA ,PLASMODIUM ,LAND use ,ENVIRONMENTAL risk ,SPATIAL variation ,Q fever ,ALPHAVIRUSES - Abstract
Background: Plasmodium knowlesi is a zoonotic parasite that causes malaria in humans. The pathogen has a natural host reservoir in certain macaque species and is transmitted to humans via mosquitoes of the Anopheles Leucosphyrus Group. The risk of human P. knowlesi infection varies across Southeast Asia and is dependent upon environmental factors. Understanding this geographic variation in risk is important both for enabling appropriate diagnosis and treatment of the disease and for improving the planning and evaluation of malaria elimination. However, the data available on P. knowlesi occurrence are biased towards regions with greater surveillance and sampling effort. Predicting the spatial variation in risk of P. knowlesi malaria requires methods that can both incorporate environmental risk factors and account for spatial bias in detection. Methods & results: We extend and apply an environmental niche modelling framework as implemented by a previous mapping study of P. knowlesi transmission risk which included data up to 2015. We reviewed the literature from October 2015 through to March 2020 and identified 264 new records of P. knowlesi, with a total of 524 occurrences included in the current study following consolidation with the 2015 study. The modelling framework used in the 2015 study was extended, with changes including the addition of new covariates to capture the effect of deforestation and urbanisation on P. knowlesi transmission. Discussion: Our map of P. knowlesi relative transmission suitability estimates that the risk posed by the pathogen is highest in Malaysia and Indonesia, with localised areas of high risk also predicted in the Greater Mekong Subregion, The Philippines and Northeast India. These results highlight areas of priority for P. knowlesi surveillance and prospective sampling to address the challenge the disease poses to malaria elimination planning. Author summary: Plasmodium knowlesi is a parasite that can cause malaria when it infects humans. Although most people do not experience severe illness from Plasmodium knowlesi infection, a small number will develop serious or even fatal disease. The parasite is found naturally in some monkeys throughout Southeast Asia, and spreads from these monkeys to humans through mosquitoes. Previous research predicted where the risk of being infected is highest according to what we know about the environment across Southeast Asia, such as if there are forests in an area or if the altitude is high. In this work, we extend this previous research with more up-to-date data on environmental conditions and infections to predict the risk of being infected with Plasmodium knowlesi. We show that the risk Plasmodium knowlesi poses to humans is high across much of Southeast Asia, and that the disease will continue to challenge national goals to eliminate malaria. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial
- Author
-
Grigg, Matthew J., William, Timothy, Menon, Jayaram, Barber, Bridget E., Wilkes, Christopher S., Rajahram, Giri S., Edstein, Michael D., Auburn, Sarah, Price, Ric N., Yeo, Tsin W., and Anstey, Nicholas M.
- Published
- 2016
14. Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance
- Author
-
Grigg, Matthew J., William, Timothy, Piera, Kim A., Rajahram, Giri S., Jelip, Jenarun, Aziz, Ammar, Menon, Jayaram, Marfurt, Jutta, Price, Ric N., Auburn, Sarah, Barber, Bridget E., Yeo, Tsin W., and Anstey, Nicholas M.
- Published
- 2018
- Full Text
- View/download PDF
15. The effect of regularly dosed paracetamol versus no paracetamol on renal function in Plasmodium knowlesi malaria (PACKNOW): study protocol for a randomised controlled trial
- Author
-
Cooper, Daniel J., Plewes, Katherine, Grigg, Matthew J., Rajahram, Giri S., Piera, Kim A., William, Timothy, Chatfield, Mark D., Yeo, Tsin Wen, Dondorp, Arjen M., Anstey, Nicholas M., and Barber, Bridget E.
- Published
- 2018
- Full Text
- View/download PDF
16. Falling Plasmodium knowlesi malaria death rate among adults despite rising incidence, Sabah, Malaysia, 2010-2014
- Author
-
Rajahram, Giri S., Barber, Bridget E., William, Timothy, Grigg, Matthew J., Menon, Jayaram, Yeo, Tsin W., and Anstey, Nicholas M.
- Subjects
Malaria -- Causes of -- Control -- Research ,Plasmodium -- Physiological aspects -- Research ,Health - Abstract
Plasmodium knowlesi is the most common cause of malaria in East Malaysia, and the incidence of disease is increasing despite intensive control efforts that have substantially reduced the incidence of [...]
- Published
- 2016
- Full Text
- View/download PDF
17. Quantifcation of parasite clearance in Plasmodium knowlesi infections.
- Author
-
Thurai Rathnam, Jeyamalar T., Grigg, Matthew J., Dini, Saber, William, Timothy, Sakam, Sitti Saimah, Cooper, Daniel J., Rajahram, Giri S., Barber, Bridget E., Anstey, Nicholas M., Haghiri, Ali, Rajasekhar, Megha, and Simpson, Julie A.
- Abstract
Background The incidence of zoonotic Plasmodium knowlesi infections in humans is rising in Southeast Asia, leading to clinical studies to monitor the efficacy of anti-malarial treatments for knowlesi malaria. One of the key outcomes of anti-malarial drug efficacy is parasite clearance. For Plasmodium falciparum, parasite clearance is typically estimated using a two-stage method, that involves estimating parasite clearance for individual patients followed by pooling of individual estimates to derive population estimates. An alternative approach is Bayesian hierarchical modelling which simultaneously analyses all parasite-time patient profiles to determine parasite clearance. This study compared these methods for estimating parasite clearance in P. knowlesi treatment efficacy studies, with typically fewer parasite measurements per patient due to high susceptibility to anti-malarials. Methods Using parasite clearance data from 714 patients with knowlesi malaria and enrolled in three trials, the Worldwide Antimalarial Resistance Network (WWARN) Parasite Clearance Estimator (PCE) standard two-stage approach and Bayesian hierarchical modelling were compared. Both methods estimate the parasite clearance rate from a model that incorporates a lag phase, slope, and tail phase for the parasitaemia profiles. Results The standard two-stage approach successfully estimated the parasite clearance rate for 678 patients, with 36 (5%) patients excluded due to an insufficient number of available parasitaemia measurements. The Bayesian hierarchical estimation method was applied to the parasitaemia data of all 714 patients. Overall, the Bayesian method estimated a faster population mean parasite clearance (0.36/h, 95% credible interval [0.18, 0.65]) compared to the standard two-stage method (0.26/h, 95% confidence interval [0.11, 0.46]), with better model fits (compared visually). Artemisinin-based combination therapy (ACT) is more effective in treating P. knowlesi than chloroquine, as confirmed by both methods, with a mean estimated parasite clearance half-life of 2.5 and 3.6 h, respectively using the standard two-stage method, and 1.8 and 2.9 h using the Bayesian method. Conclusion For clinical studies of P. knowlesi with frequent parasite measurements, the standard two-stage approach (WWARN’s PCE) is recommended as this method is straightforward to implement. For studies with fewer parasite measurements per patient, the Bayesian approach should be considered. Regardless of method used, ACT is more efficacious than chloroquine, confirming the findings of the original trials. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Diagnostic accuracy and limit of detection of ten malaria parasite lactate dehydrogenase-based rapid tests for Plasmodium knowlesi and P. falciparum.
- Author
-
Tan, Angelica F., Sakam, Sitti Saimah binti, Rajahram, Giri S., William, Timothy, Abd Rachman Isnadi, Mohammad Faruq, Daim, Sylvia, Barber, Bridget E., Kho, Steven, Sutherland, Colin J., Anstey, Nicholas M., Yerlikaya, Seda, van Schalkwyk, Donelly A., and Grigg, Matthew J.
- Subjects
PLASMODIUM ,DETECTION limit ,LACTATE dehydrogenase ,LACTATES ,INVERSE relationships (Mathematics) ,DIAGNOSIS methods - Abstract
Background: Plasmodium knowlesi causes zoonotic malaria across Southeast Asia. First-line diagnostic microscopy cannot reliably differentiate P. knowlesi from other human malaria species. Rapid diagnostic tests (RDTs) designed for P. falciparum and P. vivax are used routinely in P. knowlesi co-endemic areas despite potential cross-reactivity for species-specific antibody targets. Methods: Ten RDTs were evaluated: nine to detect clinical P. knowlesi infections from Malaysia, and nine assessing limit of detection (LoD) for P. knowlesi (PkA1-H.1) and P. falciparum (Pf3D7) cultures. Targets included Plasmodium-genus parasite lactate dehydrogenase (pan-pLDH) and P. vivax (Pv)-pLDH. Results: Samples were collected prior to antimalarial treatment from 127 patients with microscopy-positive PCR-confirmed P. knowlesi monoinfections. Median parasitaemia was 788/µL (IQR 247-5,565/µL). Pan-pLDH sensitivities ranged from 50.6% (95% CI 39.6-61.5) (SD BIOLINE) to 87.0% (95% CI 75.1-94.6) (First Response® and CareStart™ PAN) compared to reference PCR. Pv-pLDH RDTs detected P. knowlesi with up to 92.0% (95% CI 84.3-96.7%) sensitivity (Biocredit™). For parasite counts =200/µL, pan-pLDH (Standard Q) and Pv-pLDH RDTs exceeded 95% sensitivity. Specificity of RDTs against 26 PCR-confirmed negative controls was 100%. Sensitivity of six highest performing RDTs were not significantly different when comparing samples taken before and after (median 3 hours) antimalarial treatment. Parasite ring stages were present in 30% of pre-treatment samples, with ring stage proportions (mean 1.9%) demonstrating inverse correlation with test positivity of Biocredit™ and two CareStart™ RDTs. For cultured P. knowlesi, CareStart™ PAN demonstrated the lowest LoD at 25 parasites/µL; LoDs of other pan-pLDH ranged from 98 to >2000 parasites/µL. Pv-pLDH LoD for P. knowlesi was 49 parasites/µL. No false-positive results were observed in either P. falciparum-pLDH or histidine-rich-protein-2 channels. Conclusion: Selected RDTs demonstrate sufficient performance for detection of major human malaria species including P. knowlesi in co-endemic areas where microscopy is not available, particularly for higher parasite counts, although cannot reliably differentiate among non-falciparum malaria. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Effect of Regularly Dosed Acetaminophen vs No Acetaminophen on Renal Function in Plasmodium knowlesi Malaria (PACKNOW): A Randomized, Controlled Trial.
- Author
-
Cooper, Daniel J, Grigg, Matthew J, Plewes, Katherine, Rajahram, Giri S, Piera, Kim A, William, Timothy, Menon, Jayaram, Koleth, Glenn, Edstein, Michael D, Birrell, Geoffrey W, Wattanakul, Thanaporn, Tarning, Joel, Patel, Aatish, Yeo, Tsin Wen, Dondorp, Arjen M, Anstey, Nicholas M, and Barber, Bridget E
- Subjects
DRUG therapy for malaria ,ACUTE kidney failure prevention ,GLOMERULAR filtration rate ,ACETAMINOPHEN ,HEMOLYSIS & hemolysins ,OXIDATIVE stress ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,LONGITUDINAL method ,CREATININE - Abstract
Background Acetaminophen inhibits cell-free hemoglobin-induced lipid peroxidation and improves renal function in severe falciparum malaria but has not been evaluated in other infections with prominent hemolysis, including Plasmodium knowlesi malaria. Methods PACKNOW was an open-label, randomized, controlled trial of acetaminophen (500 mg or 1000 mg every 6 hours for 72 hours) vs no acetaminophen in Malaysian patients aged ≥5 years with knowlesi malaria of any severity. The primary end point was change in creatinine at 72 hours. Secondary end points included longitudinal changes in creatinine in patients with severe malaria or acute kidney injury (AKI), stratified by hemolysis. Results During 2016–2018, 396 patients (aged 12–96 years) were randomized to acetaminophen (n = 199) or no acetaminophen (n = 197). Overall, creatinine fell by a mean (standard deviation) 14.9% (18.1) in the acetaminophen arm vs 14.6% (16.0) in the control arm (P = .81). In severe disease, creatinine fell by 31.0% (26.5) in the acetaminophen arm vs 20.4% (21.5) in the control arm (P = .12), and in those with hemolysis by 35.8% (26.7) and 19% (16.6), respectively (P = .07). No difference was seen overall in patients with AKI; however, in those with AKI and hemolysis, creatinine fell by 34.5% (20.7) in the acetaminophen arm vs 25.9% (15.8) in the control arm (P = .041). Mixed-effects modeling demonstrated a benefit of acetaminophen at 72 hours (P = .041) and 1 week (P = .002) in patients with severe malaria and with AKI and hemolysis (P = .027 and P = .002, respectively). Conclusions Acetaminophen did not improve creatinine among the entire cohort but may improve renal function in patients with severe knowlesi malaria and in those with AKI and hemolysis. Clinical Trials Registration NCT03056391. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Deaths due to Plasmodium knowlesi malaria in Sabah, Malaysia: association with reporting as Plasmodium malariae and delayed parenteral artesunate
- Author
-
Rajahram Giri S, Barber Bridget E, William Timothy, Menon Jayaram, Anstey Nicholas M, and Yeo Tsin W
- Subjects
Malaria ,Plasmodium knowlesi ,Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background The simian parasite Plasmodium knowlesi is recognized as a common cause of severe and fatal human malaria in Sabah, Malaysia, but is morphologically indistinguishable from and still commonly reported as Plasmodium malariae, despite the paucity of this species in Sabah. Since December 2008 Sabah Department of Health has recommended intravenous artesunate and referral to a general hospital for all severe malaria cases of any species. This paper reviews all malaria deaths in Sabah subsequent to the introduction of these measures. Reporting of malaria deaths in Malaysia is mandatory. Methods Details of reported malaria deaths during 2010-2011 were reviewed to determine the proportion of each Plasmodium species. Demographics, clinical presentations and management of severe malaria caused by each species were compared. Results Fourteen malaria deaths were reported, comprising seven Plasmodium falciparum, six P. knowlesi and one Plasmodium vivax (all PCR-confirmed). Of the six P. knowlesi deaths, five were attributable to knowlesi malaria and one was attributable to P. knowlesi-associated enterobacter sepsis. Patients with directly attributable P. knowlesi deaths (N = 5) were older than those with P. falciparum (median age 51 [IQR 50-65] vs 22 [IQR 9-55] years, p = 0.06). Complications in fatal P. knowlesi included respiratory distress (N = 5, 100%), hypotension (N = 4, 80%), and renal failure (N = 4, 80%). All patients with P. knowlesi were reported as P. malariae by microscopy. Only two of five patients with severe knowlesi malaria on presentation received immediate parenteral anti-malarial treatment. The patient with P. vivax-associated severe illness did not receive parenteral treatment. In contrast six of seven patients with severe falciparum malaria received immediate parenteral treatment. Conclusion Plasmodium knowlesi was responsible, either directly or through gram-negative bacteraemia, for almost half of malaria deaths in Sabah. Patients with severe non-falciparum malaria were less likely to receive immediate parenteral therapy. This highlights the need in Sabah for microscopically diagnosed P. malariae to be reported as P. knowlesi to improve recognition and management of this potentially fatal species. Clinicians need to be better informed of the potential for severe and fatal malaria from non-falciparum species, and the need to treat all severe malaria with immediate intravenous artesunate.
- Published
- 2012
- Full Text
- View/download PDF
21. Plasmodium knowlesi Malaria in Sabah, Malaysia, 2015–2017: Ongoing Increase in Incidence Despite Near-elimination of the Human-only Plasmodium Species.
- Author
-
Cooper, Daniel J, Rajahram, Giri S, William, Timothy, Jelip, Jenarun, Mohammad, Rashidah, Benedict, Joseph, Alaza, Danshy A, Malacova, Eva, Yeo, Tsin W, Grigg, Matthew J, Anstey, Nicholas M, and Barber, Bridget E
- Subjects
- *
MALARIA prevention , *CONFIDENCE intervals , *MALARIA , *MICROSCOPY , *POLYMERASE chain reaction , *PROTOZOA , *DESCRIPTIVE statistics - Abstract
Background Malaysia aims to eliminate malaria by 2020. However, while cases of Plasmodium falciparum and Plasmodium vivax have decreased substantially, the incidence of zoonotic malaria from Plasmodium knowlesi continues to increase, presenting a major challenge to regional malaria control efforts. Here we report incidence of all Plasmodium species in Sabah, including zoonotic P. knowlesi , during 2015–2017. Methods Microscopy-based malaria notification data and polymerase chain reaction (PCR) results were obtained from the Sabah Department of Health and State Public Health Laboratory, respectively, from January 2015 to December 2017. From January 2016 this was complemented by a statewide prospective hospital surveillance study. Databases were matched, and species was determined by PCR, or microscopy if PCR was not available. Results A total of 3867 malaria cases were recorded between 2015 and 2017, with PCR performed in 93%. Using PCR results, and microscopy if PCR was unavailable, P. knowlesi accounted for 817 (80%), 677 (88%), and 2030 (98%) malaria cases in 2015, 2016, and 2017, respectively. P. falciparum accounted for 110 (11%), 45 (6%), and 23 (1%) cases and P. vivax accounted for 61 (6%), 17 (2%), and 8 (0.4%) cases, respectively. Of those with P. knowlesi , the median age was 35 (interquartile range: 24–47) years, and 85% were male. Conclusions Malaysia is approaching elimination of the human-only Plasmodium species. However, the ongoing increase in P. knowlesi incidence presents a major challenge to malaria control and warrants increased focus on knowlesi-specific prevention activities. Wider molecular surveillance in surrounding countries is required. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. Deaths From Plasmodium knowlesi Malaria: Case Series and Systematic Review.
- Author
-
Rajahram, Giri S, Cooper, Daniel J, William, Timothy, Grigg, Matthew J, Anstey, Nicholas M, and Barber, Bridget E
- Subjects
- *
DRUG therapy for malaria , *MALARIA diagnosis , *CARDIOVASCULAR diseases , *DIAGNOSTIC errors , *INTRAVENOUS therapy , *MALARIA , *METABOLIC disorders , *PUBLIC health laws , *SYSTEMATIC reviews , *COMORBIDITY , *DISEASE incidence , *ODDS ratio ,RISK of malaria - Abstract
Background Plasmodium knowlesi causes severe and fatal malaria, and incidence in Southeast Asia is increasing. Factors associated with death are not clearly defined. Methods All malaria deaths in Sabah, Malaysia, from 2015 to 2017 were identified from mandatory reporting to the Sabah Department of Health. Case notes were reviewed, and a systematic review of these and all previously reported fatal P. knowlesi cases was conducted. Case fatality rates (CFRs) during 2010–2017 were calculated using incidence data from the Sabah Department of Health. Results Six malaria deaths occurred in Sabah during 2015–2017, all from P. knowlesi. Median age was 40 (range, 23–58) years; 4 cases (67%) were male. Three (50%) had significant cardiovascular comorbidities and 1 was pregnant. Delays in administering appropriate therapy contributed to 3 (50%) deaths. An additional 26 fatal cases were included in the systematic review. Among all 32 cases, 18 (56%) were male; median age was 56 (range, 23–84) years. Cardiovascular-metabolic disease, microscopic misdiagnosis, and delay in commencing intravenous treatment were identified in 11 of 32 (34%), 26 of 29 (90%), and 11 of 31 (36%) cases, respectively. The overall CFR during 2010–2017 was 2.5/1000: 6.0/1000 for women and 1.7/1000 for men (P =.01). Independent risk factors for death included female sex (odds ratio, 2.6; P =.04), and age ≥45 years (odds ratio, 4.7; P <.01). Conclusions Earlier presentation, more rapid diagnosis, and administration of intravenous artesunate may avoid fatal outcomes, particularly in females, older adults, and patients with cardiovascular comorbidities. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. Haemophagocytic lymphohistiocytosis secondary to dengue fever: a case report.
- Author
-
Cheo, S. W., Rashid, W. N. F. A. Abdul, Ho, C. V., Akhbar, Rosdina Z. Ahmad, Low, Q. J., and Rajahram, Giri S.
- Published
- 2021
- Full Text
- View/download PDF
24. Efficacy of Artesunate-mefloquine for Chloroquineresistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial.
- Author
-
Grigg, Matthew J., William, Timothy, Menon, Jayaram, Barber, Bridget E., Wilkes, Christopher S., Rajahram, Giri S., Edstein, Michael D., Auburn, Sarah, Price, Ric N., Yeo, Tsin W., and Anstey, Nicholas M.
- Subjects
MEFLOQUINE ,PLASMODIUM vivax ,MALARIA treatment ,ARTEMISININ ,DRUG efficacy ,THERAPEUTICS - Abstract
Background. Chloroquine (CQ)-resistant Plasmodium vivax is increasingly reported throughout southeast Asia. The efficacy of CQ and alternative artemisinin combination therapies (ACTs) for vivax malaria in Malaysia is unknown. Methods. A randomized, controlled trial of CQ vs artesunate-mefloquine (AS-MQ) for uncomplicated vivax malaria was conducted in 3 district hospitals in Sabah, Malaysia. Primaquine was administered on day 28. The primary outcome was the cumulative risk of treatment failure by day 28 by Kaplan-Meier analysis. Results. From 2012 to 2014, 103 adults and children were enrolled. Treatment failure by day 28 was 61.1% (95% confidence interval [CI], 46.8-75.6) after CQ and 0% (95% CI, 0-.08) following AS-MQ (P < .001), of which 8.2% (95% CI, 2.5-9.6) were early treatment failures. All patients with treatment failure had therapeutic plasma CQ concentrations at day 7. Compared with CQ, AS-MQ was associated with faster parasite clearance (normalized clearance slope, 0.311 vs 0.127; P < .001) and fever clearance (mean, 19.0 vs 37.7 hours; P = .001) and with lower risk of anemia at day 28 (odds ratio = 3.7; 95% CI, 1.5-9.3; P = .005). Gametocytes were present at day 28 in 23.8% (10/42) of patients following CQ vs none with AS-MQ (P < .001). AS-MQ resulted in lower bed occupancy: 4037 vs 6510 days/1000 patients (incidence rate ratio 0.62; 95% CI, .60-.65; P < .001). One patient developed severe anemia not regarded as related to their AS-MQ treatment. Conclusions. High-grade CQ-resistant P. vivax is prevalent in eastern Malaysia. AS-MQ is an efficacious ACT for all malaria species. Wider CQ-efficacy surveillance is needed in vivax-endemic regions with earlier replacement with ACT when treatment failure is detected. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
25. World Malaria Report: time to acknowledge Plasmodium knowlesi malaria.
- Author
-
Barber, Bridget E., Rajahram, Giri S., Grigg, Matthew J., William, Timothy, and Anstey, Nicholas M.
- Subjects
- *
MALARIA prevention , *PLASMODIUM falciparum , *PLASMODIUM vivax , *PREVENTIVE medicine ,MALARIA transmission - Abstract
Background: The 2016 World Health Organization (WHO) World Malaria Report documents substantial progress towards control and elimination of malaria. However, major challenges remain. In some regions of Southeast Asia, the simian parasite Plasmodium knowlesi has emerged as an important cause of human malaria, and the authors believe this species warrants regular inclusion in the World Malaria Report. Main text: Plasmodium knowlesi is the most common cause of malaria in Malaysia, and cases have also been reported in nearly all countries of Southeast Asia. Outside of Malaysia, P. knowlesi is frequently misdiagnosed by microscopy as Plasmodium falciparum or Plasmodium vivax. Thus, P. knowlesi may be underdiagnosed in affected regions and its true incidence underestimated. Acknowledgement in the World Malaria Report of the regional importance of P. knowlesi will facilitate efforts to improve surveillance of this emerging parasite. Furthermore, increased recognition will likely lead to improved delivery of effective treatment for this potentially fatal infection, as has occurred in Malaysia where P. knowlesi case-fatality rates have fallen despite rising incidence. In a number of knowlesi-endemic countries, substantial progress has been made towards the elimination of P. vivax and P. falciparum. However, efforts to eliminate these human-only species should not preclude efforts to reduce human malaria from P. knowlesi. The regional importance of knowlesi malaria was recognized by the WHO with its recent Evidence Review Group meeting on knowlesi malaria to address strategies for prevention and mitigation. Conclusion: The WHO World Malaria Report has an appropriate focus on falciparum and vivax malaria, the major causes of global mortality and morbidity. However, the authors hope that in future years this important publication will also incorporate data on the progress and challenges in reducing knowlesi malaria in regions where transmission occurs. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
26. Chapter One - Knowlesi malaria: Human risk factors, clinical spectrum, and pathophysiology.
- Author
-
Anstey, Nicholas M., Grigg, Matthew J., Rajahram, Giri S., Cooper, Daniel J., William, Timothy, Kho, Steven, and Barber, Bridget E.
- Subjects
- *
ERYTHROCYTE deformability , *HUMAN life cycle , *MALARIA , *ERYTHROCYTES , *DISEASE risk factors , *ACUTE kidney failure - Abstract
Plasmodium knowlesi is endemic across Southeast Asia, and is the commonest cause of zoonotic malaria. The spectrum of clinical disease from P. knowlesi infection ranges from asymptomatic infection, through to severe malaria and death. Over 90% of clinical disease occurs in adults, mostly living in forest edge areas undergoing intensive land use change. With a 24-h asexual life cycle in humans, high parasite counts are possible, but most clinical cases of knowlesi malaria are uncomplicated with low parasitaemia. In co-endemic areas, median parasitaemia in knowlesi malaria is lower than that seen in vivax and falciparum malaria, suggesting a lower fever threshold. Severe malaria occurs in 6-9% of symptomatic adults. Manifestations of severe malaria from P. knowlesi are similar to those seen with falciparum malaria, with the notable absence of coma. Age, parasitaemia, cardiovascular comorbidities and delayed diagnosis are risk factors for severe disease and death, which are only seen in adults. Thrombocytopenia is near-universal in adults, likely related to platelet-red cell binding and clearance. Mechanisms underlying the microvascular sludging seen in fatal disease in non-natural primate hosts and the microvascular accumulation of parasites in fatal human disease are not clear. Marked reductions in deformability of both infected and uninfected red blood cells are associated with disease severity in both humans and other non-natural primate hosts, likely contributing to impaired microvascular perfusion and organ dysfunction. Endothelial activation, endothelial dysfunction, glycocalyx degradation and haemolysis are also associated with, and likely contribute to, severe disease and organ dysfunction, particularly acute kidney injury. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. The effect of regularly dosed paracetamol versus no paracetamol on renal function in <italic>Plasmodium knowlesi</italic> malaria (PACKNOW): study protocol for a randomised controlled trial.
- Author
-
Cooper, Daniel J., Plewes, Katherine, Grigg, Matthew J., Rajahram, Giri S., Piera, Kim A., William, Timothy, Chatfield, Mark D., Yeo, Tsin Wen, Dondorp, Arjen M., Anstey, Nicholas M., and Barber, Bridget E.
- Subjects
ACETAMINOPHEN ,MALARIA ,ACUTE kidney failure ,CHRONIC kidney failure ,CARDIOVASCULAR diseases - Abstract
Background:
Plasmodium knowlesi is the most common cause of human malaria in Malaysia. Acute kidney injury (AKI) is a frequent complication. AKI of any cause can have long-term consequences, including increased risk of chronic kidney disease, adverse cardiovascular events and increased mortality. Additional management strategies are therefore needed to reduce the frequency and severity of AKI in malaria. In falciparum malaria, cell-free haemoglobin (CFHb)-mediated oxidative damage contributes to AKI. The inexpensive and widely available drug paracetamol inhibits CFHb-induced lipid peroxidation via reduction of ferryl haem to the less toxic Fe3+ state, and has been shown to reduce oxidative damage and improve renal function in patients with sepsis complicated by haemolysis as well as in falciparum malaria. This study aims to assess the ability of regularly dosed paracetamol to reduce the incidence and severity of AKI in knowlesi malaria by attenuating haemolysis-induced oxidative damage. Methods: PACKNOW is a two-arm, open-label randomised controlled trial of adjunctive paracetamol versus no paracetamol in patients aged ≥ 5 years with knowlesi malaria, conducted over a 2-year period at four hospital sites in Sabah, Malaysia. The primary endpoint of change in creatinine from enrolment to 72 h will be evaluated by analysis of covariance (ANCOVA) using enrolment creatinine as a covariate. Secondary endpoints include longitudinal changes in markers of oxidative stress (plasma F2 -isoprostanes and isofurans) and markers of endothelial activation/Weibel–Palade body release (angiopoietin-2, von Willebrand Factor, P-selectin, osteoprotegerin) over 72 h, as well as blood and urine biomarkers of AKI. This study will be powered to detect a difference between the two treatment arms in a clinically relevant population including adults and children with knowlesi malaria of any severity. Discussion: Paracetamol is widely available and has an excellent safety profile; if a renoprotective effect is demonstrated, this trial will support the administration of regularly dosed paracetamol to all patients with knowlesi malaria. The secondary outcomes in this study will provide further insights into the pathophysiology of haemolysis-induced oxidative damage and acute kidney injury in knowlesi malaria and other haemolytic diseases. Trial registration: Clinicaltrials.gov,NCT03056391 . Registered on 12 October 2016. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
28. Chapter Three - Plasmodium knowlesi detection methods for human infections--Diagnosis and surveillance.
- Author
-
Grigg, Matthew J., Lubis, Inke N., Tetteh, Kevin K. A., Barber, Bridget E., William, Timothy, Rajahram, Giri S., Tan, Angelica F., Sutherland, Colin J., Noviyanti, Rintis, Drakeley, Chris J., Britton, Sumudu, and Anstey, Nicholas M.
- Subjects
- *
PLASMODIUM , *DIAGNOSIS , *TREATMENT delay (Medicine) , *DIAGNOSIS methods , *MALARIA prevention , *INFECTION - Abstract
Within the overlapping geographical ranges of P. knowlesi monkey hosts and vectors in Southeast Asia, an estimated 1.5 billion people are considered at risk of infection. P. knowlesi can cause severe disease and death, the latter associated with delayed treatment occurring from misdiagnosis. Although microscopy is a sufficiently sensitive first-line tool for P. knowlesi detection for most low-level symptomatic infections, misdiagnosis as other Plasmodium species is common, and the majority of asymptomatic infections remain undetected. Current point-of-care rapid diagnostic tests demonstrate insufficient sensitivity and poor specificity for differentiating P. knowlesi from other Plasmodium species. Molecular tools including nested, real-time, and single-step PCR, and loop-mediated isothermal amplification (LAMP), are sensitive for P. knowlesi detection. However, higher cost and inability to provide the timely point-of-care diagnosis needed to guide appropriate clinical management has limited their routine use in most endemic clinical settings. P. knowlesi is likely underdiagnosed across the region, and improved diagnostic and surveillance tools are required. Reference laboratory molecular testing of malaria cases for both zoonotic and non-zoonotic Plasmodium species needs to be more widely implemented by National Malaria Control Programs across Southeast Asia to accurately identify the burden of zoonotic malaria and more precisely monitor the success of human-only malaria elimination programs. The implementation of specific serological tools for P. knowlesi would assist in determining the prevalence and distribution of asymptomatic and submicroscopic infections, the absence of transmission in certain areas, and associations with underlying land use change for future spatially targeted interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Chapter Two - Clinical management of Plasmodium knowlesi malaria.
- Author
-
Barber, Bridget E., Grigg, Matthew J., Cooper, Daniel J., van Schalkwyk, Donelly A., William, Timothy, Rajahram, Giri S., and Anstey, Nicholas M.
- Subjects
- *
PLASMODIUM , *MALARIA , *ACUTE kidney failure , *MULTIPLE organ failure - Abstract
The zoonotic parasite Plasmodium knowlesi has emerged as an important cause of human malaria in parts of Southeast Asia. The parasite is indistinguishable by microscopy from the more benign P. malariae, but can result in high parasitaemias with multiorgan failure, and deaths have been reported. Recognition of severe knowlesi malaria, and prompt initiation of effective therapy is therefore essential to prevent adverse outcomes. Here we review all studies reporting treatment of uncomplicated and severe knowlesi malaria. We report that although chloroquine is effective for the treatment of uncomplicated knowlesi malaria, artemisinin combination treatment is associated with faster parasite clearance times and lower rates of anaemia during follow-up, and should be considered the treatment of choice, particularly given the risk of administering chloroquine to drug-resistant P. vivax or P. falciparum misdiagnosed as P. knowlesi malaria in co-endemic areas. For severe knowlesi malaria, intravenous artesunate has been shown to be highly effective and associated with reduced case-fatality rates, and should be commenced without delay. Regular paracetamol may also be considered for patients with severe knowlesi malaria or for those with acute kidney injury, to attenuate the renal damage resulting from haemolysis-induced lipid peroxidation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial.
- Author
-
Grigg, Matthew J, William, Timothy, Menon, Jayaram, Dhanaraj, Prabakaran, Barber, Bridget E, Wilkes, Christopher S, von Seidlein, Lorenz, Rajahram, Giri S, Pasay, Cielo, McCarthy, James S, Price, Ric N, Anstey, Nicholas M, and Yeo, Tsin W
- Subjects
- *
MALARIA treatment , *ARTEMISININ , *PLASMODIUM , *MEFLOQUINE , *CHLOROQUINE , *RANDOMIZED controlled trials , *DRUG therapy for malaria , *ANTIMALARIALS , *COMBINATION drug therapy , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *ORAL drug administration , *PROTOZOA , *RESEARCH , *RESEARCH funding , *EVALUATION research , *THERAPEUTICS - Abstract
Background: The zoonotic parasite Plasmodium knowlesi has become the most common cause of human malaria in Malaysia and is present throughout much of southeast Asia. No randomised controlled trials have been done to identify the optimum treatment for this emerging infection. We aimed to compare artesunate-mefloquine with chloroquine to define the optimum treatment for uncomplicated P knowlesi malaria in adults and children.Methods: We did this open-label, randomised controlled trial at three district hospitals in Sabah, Malaysia. Patients aged 1 year or older with uncomplicated P knowlesi malaria were randomly assigned, via computer-generated block randomisation (block sizes of 20), to receive oral artesunate-mefloquine (target dose 12 mg/kg artesunate and 25 mg/kg mefloquine) or chloroquine (target dose 25 mg/kg). Research nursing staff were aware of group allocation, but allocation was concealed from the microscopists responsible for determination of the primary endpoint, and study participants were not aware of drug allocation. The primary endpoint was parasite clearance at 24 h. Analysis was by modified intention to treat. This study is registered with ClinicalTrials.gov, number NCT01708876.Findings: Between Oct 16, 2012, and Dec 13, 2014, we randomly assigned 252 patients to receive either artesunate-mefloquine (n=127) or chloroquine (n=125); 226 (90%) patients comprised the modified intention-to-treat population. 24 h after treatment, we recorded parasite clearance in 97 (84% [95% CI 76-91]) of 115 patients in the artesunate-mefloquine group versus 61 (55% [45-64]) of 111 patients in the chloroquine group (difference in proportion 29% [95% CI 18·0-40·8]; p<0·0001). Parasite clearance was faster in patients given artesunate-mefloquine than in those given chloroquine (18·0 h [range 6·0-48·0] vs 24·0 h [6·0-60·0]; p<0·0001), with faster clearance of ring stages in the artesunate-mefloquine group (mean time to 50% clearance of baseline parasites 8·6 h [95% CI 7·9-9·4] vs 13·8 h [12·1-15·4]; p<0·0001). Risk of anaemia within 28 days was lower in patients in the artesunate-mefloquine group (71 [62%; 95% CI 52·2-70·6]) than in those in the chloroquine group (83 [75%; 65·6-82·5]; p=0·035). Gametocytaemia as detected by PCR for pks25 was present in 44 (86%) of 51 patients in the artesunate-mefloquine group and 41 (84%) of 49 patients in the chloroquine group at baseline, and in three (6%) of 49 patients and two (4%) of 48 patients, respectively, at day 7. Fever clearance was faster in the artesunate-mefloquine group (mean 11·5 h [95% CI 8·3-14·6]) than in the chloroquine group (14·8 h [11·7-17·8]; p=0·034). Bed occupancy was 2426 days per 1000 patients in the artesunate-mefloquine group versus 2828 days per 1000 patients in the chloroquine group (incidence rate ratio 0·858 [95% CI 0·812-0·906]; p<0·0001). One (<1%) patient in the artesunate-mefloquine group had a serious neuropsychiatric event regarded as probably related to study drug.Interpretation: Artesunate-mefloquine is highly efficacious for treatment of uncomplicated P knowlesi malaria. The rapid therapeutic response of the drug offers significant advantages compared with chloroquine monotherapy and supports a unified treatment policy for artemisinin-based combination therapy for all Plasmodium species in co-endemic areas.Funding: Malaysian Ministry of Health, Australian National Health and Medical Research Council, and Asia Pacific Malaria Elimination Network. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.